Now prescribing BPC-157, TB-500, Semax, MOTS-c and Epitalon

PepScribe
Not FDA-approved · Educational only

Thymosin Alpha-1: what the research says. | Reddit

Last updated October 27, 2026

More: Clinical standards · Pharmacy partners · Is PepScribe legit?

A 28-amino-acid immune-modulating peptide originally isolated from the thymus gland in 1977. Approved as Zadaxin in 30+ countries with a substantial body of human clinical data. Not FDA-approved in the US and not on FDA’s 503A Bulks List.

Regulatory notice: Thymosin Alpha-1 is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Thymosin Alpha-1 was not among them.

This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.

What Thymosin Alpha-1 is.

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland, the organ responsible for T-cell maturation and immune system education. It was first characterized by Allan Goldstein at the National Institutes of Health in 1977, making it one of the earliest peptides studied for immune modulation. Enrico Garaci and colleagues at the University of Rome later conducted much of the clinical development work.

Thymosin Alpha-1 has a substantial body of human clinical data. It’s marketed as Zadaxin (thymalfasin) and approved as a pharmaceutical product in over 30 countries, including China, India, and across Southeast Asia, for hepatitis B, hepatitis C, and as an immune adjunct in certain cancers. In the US, it is not FDA-approved and is not on FDA’s 503A Bulks List.

How it works.

T-cell maturation

Immune cell development

Research by Goldstein et al. (published across multiple papers in PNAS, 1977–1981) established that Thymosin Alpha-1 promotes maturation and differentiation of T-cells from progenitor cells. T-cells are the immune system’s primary adaptive defense, responsible for identifying and eliminating infected or abnormal cells. This mechanism is well-characterized and forms the basis of its approved uses.

Dendritic cell activation

Antigen presentation

A 2003 study by Romani et al. in Blood demonstrated that Tα1 activates dendritic cells through Toll-like receptor 9 (TLR9) signaling. Dendritic cells act as the immune system’s scouts, they identify threats and present them to T-cells for targeted response. This makes the adaptive immune response more precise.

NK cell enhancement

Natural killer cell activity

Clinical studies by Garaci et al. (1995, International Journal of Immunopharmacology) demonstrated that Tα1 enhances natural killer (NK) cell activity in hepatitis patients, the innate immune cells that provide first-line defense against viral infections and abnormal cell growth.

Immune modulation

Balanced immune response

A 2007 review by Romani et al. in Annals of the New York Academy of Sciences described Tα1’s bidirectional immune effects. Rather than simply stimulating the immune system, Tα1 modulates it, supporting function when underactive and tempering excessive responses. This is why it has been studied in both immune deficiency and autoimmune contexts.

What the research suggests.

Thymosin Alpha-1 has a stronger evidence base than most peptides on this list. Multiple randomized controlled trials in humans have been published, and it has regulatory approval in 30+ countries.

Hepatitis B and C

A 2022 Cochrane systematic review (Zhang et al.) pooled five RCTs covering 353 participants and found Tα1 monotherapy was roughly three-fold superior to placebo for virological response at 12 months after treatment ended; differences at end of treatment and at 6 months post-treatment were not statistically significant. An earlier meta-analysis (Yang et al., Antiviral Research, 2008; four RCTs, 199 patients) compared Tα1 to interferon alpha and reported a similarly delayed benefit pattern, lower response at end of 6-month therapy but higher response 6 months post-treatment. Garaci et al. published supporting RCT data in Hepatology and the International Journal of Immunopharmacology. Tα1 is approved as Zadaxin in multiple countries for hepatitis B; the U.S. FDA has not approved Zadaxin.

Cancer adjunct therapy

A 2010 systematic review by Maio et al. in the Annals of the New York Academy of Sciences analyzed data from over 30 clinical trials using Tα1 as an adjunct to chemotherapy. The review reported improved immune function during treatment, reduced immunosuppression from chemotherapy, and improved response rates when combined with standard protocols in hepatocellular carcinoma and melanoma.

Immune deficiency states

Clinical research by Tuthill et al. (2010, Annals of the New York Academy of Sciences) reviewed Tα1 use in immunocompromised populations, including post-surgical patients, elderly individuals, and those with chronic infections. Data suggests Tα1 may help restore T-cell counts and function. During the COVID-19 pandemic, retrospective studies from Chinese hospitals (Liu et al., 2020, Clinical Infectious Diseases) reported improved outcomes in critically ill patients who received Tα1.

Vaccine enhancement

Garaci et al. (2000, International Immunopharmacology) studied Tα1 as a vaccine adjuvant, improving immune response to influenza vaccination in elderly populations who typically have diminished vaccine responses. The data showed improved seroconversion rates, suggesting a practical application in populations with age-related immune decline.

Administration (research context).

In clinical research and the approved pharmaceutical product Zadaxin, Thymosin Alpha-1 is administered via subcutaneous injection. The established dosing in approved-market formulations is well-documented, typically involving 1.6 mg doses administered subcutaneously two to three times per week over defined treatment periods.

Because Tα1 has approved pharmaceutical formulations in other countries, its dosing and pharmacokinetic data come largely from that use abroad. That said, Tα1 is not currently on FDA’s 503A Bulks List.

This is research context, not prescribing guidance. Thymosin Alpha-1 is handled consultation-first and this information should not be interpreted as a dosing recommendation.

Side effects & safety considerations.

Tα1 has human safety data drawn from clinical trials and decades of pharmaceutical use abroad.

Common side effects

  • Injection site reactions (redness, swelling, discomfort)
  • Mild flu-like symptoms, this is expected with immune activation and usually resolves within 24–48 hours
  • Temporary fatigue or malaise

Safety profile

Across published clinical trials and decades of pharmaceutical use as Zadaxin, Tα1 has demonstrated a favorable safety profile. A 2010 review by Tuthill et al. in the Annals of the New York Academy of Sciences analyzed safety data from 4,600+ patients across multiple clinical trials and reported serious adverse events in less than 1% of patients. That said, any immune-modulating compound should be used under medical supervision, especially in individuals with autoimmune conditions.

Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.

Legal status.

Thymosin Alpha-1 is not an FDA-approved drug in the United States and is not currently on FDA’s 503A Bulks List or in Category 1.

FDA removed Tα1 from Category 2 on September 27, 2024, because the nomination was withdrawn by the nominator. FDA now lists it as a withdrawn nomination.

FDA’s Pharmacy Compounding Advisory Committee reviewed it on December 4, 2024. FDA had proposed against adding it to the 503A Bulks List, and the committee voted 17 to 4 against adding it.

Does thymosin alpha help with inflammation?

The human record points to yes in specific hospital settings, where Tα1 works as a regulator of the immune response. A 2025 systematic review and meta-analysis in severe acute pancreatitis reported that Tα1 lowered inflammation and infection through immune regulation (PMID 40599771). A 2018 review described Tα1 in sepsis as an immune modulator that activates and restores a dysregulated host response (PMID 30063866). A 2023 human study in people with post-acute sequelae of SARS-CoV-2 infection reported that Tα1 restored immune balance in lymphocytes (PMID 36989892).

This fits the two-way effect described in the mechanism section above: Tα1 supports immune function when it runs low and tempers excessive responses. The people in these studies were hospital and infectious-disease patients under specialist care. No trial in the record measured Tα1 for everyday inflammation, joint pain or recovery in healthy adults, which is how it is often discussed online. Whether it fits your situation is a call for a licensed clinician who reviews your history.

Is thymosin beta 4 the same as bpc 157?

No. They are different molecules with different origins. Thymosin beta-4 is a naturally occurring 43-amino-acid peptide (PMID 20536470). It is found in body fluids and inside cells, runs high in platelets, and has reported angiogenic and anti-inflammatory activity (PMID 27450738). Online it is often discussed under the name TB-500. BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a gastric protein (PMID 42198317). Both differ from thymosin alpha-1, a 28-amino-acid peptide.

They get mentioned together because both are discussed for tissue repair, but the human evidence differs. Thymosin beta-4 has a phase I safety study in healthy volunteers (PMID 34346165) and small randomized trials as an eye drop for dry eye (PMID 26056426) and in venous ulcers (PMID 20536470). For BPC-157, a 2025 systematic review in orthopaedic sports medicine describes the musculoskeletal healing data as preclinical (PMID 40756949).

Neither is FDA-approved, and neither is on FDA’s 503A Bulks List. FDA removed both from Category 2 in April 2026. FDA’s Pharmacy Compounding Advisory Committee voted in July 2026 to recommend both, and FDA has not acted on that vote.

Which peptide is best for inflammation?

No study in the record names a best peptide for inflammation, because none compares them head to head. What the record does show is how deep the human evidence runs for each one.

Thymosin alpha-1 has the most human data of the peptides discussed here: randomized trials and meta-analyses in hepatitis, covered above, plus a 2025 meta-analysis in severe acute pancreatitis that reported lower inflammation (PMID 40599771). Those were hospital patients. Thymosin beta-4 has small human trials, including an eye drop for severe dry eye (PMID 25826322) and a phase I safety study (PMID 34346165). For BPC-157, a 2025 systematic review describes the healing data as preclinical (PMID 40756949).

“Inflammation” also covers very different problems, from a sore tendon to an autoimmune condition to an infection. Each has its own causes and its own established options. Which approach fits depends on the cause, your history and the medicines you already take. A licensed clinician who reviews your history is the right person to weigh the record against your situation.

What is the difference between thymalin and thymosin alpha 1?

We cannot give a sourced comparison, because the research record we work from holds no study on thymalin. We make no claim about it here.

The record does cover thymulin, a thymic hormone with a similar name that is easy to confuse with it. Thymulin is produced only by thymic epithelial cells. It is a nonapeptide, nine amino acids, coupled to zinc, and the zinc gives the molecule its biological activity (PMID 19236333). In humans, zinc deficiency lowers serum thymulin activity, which is needed for T-helper cell maturation (PMID 17449604). None of the thymulin records in our source pack is a human trial.

Thymosin alpha-1 is a separate 28-amino-acid peptide first isolated from the thymus, with human trial data and approval abroad as Zadaxin, as covered above. A 2020 review lists thymulin, thymopoietin, thymosin alpha and thymosin beta as distinct thymic hormones with different spectra of activity (PMID 32700610). If you are weighing any of these, a licensed clinician can review what you have read alongside your history.

Who should not take thymosin alpha 1 peptide?

The sources we cite do not set out a contraindication list for thymosin alpha-1, and with no US approval there is no US label to point to. A 2001 pharmacy review covers its pharmacology, adverse effects, and dosage and administration (PMID 11381492).

What the record does support: Tα1 changes how the immune system behaves. It activates dendritic cells and enhances T-cell and natural killer cell activity, as covered in the mechanism section above. The safety section above flags autoimmune conditions as a reason for medical supervision with any immune-modulating compound.

Most of the human data comes from people with hepatitis, cancer, sepsis or other serious illness who were cared for in hospitals or specialist clinics. The record says little about healthy adults using it for wellness. If you have an autoimmune condition or take medicines that act on the immune system, raise that first. A licensed clinician who reviews your full history decides whether it suits you.

How long should you take thymosin alpha 1?

No human trial sets a duration for the way Tα1 is discussed online, as a general immune or wellness peptide. The durations in the record come from disease trials.

The hepatitis studies covered above ran fixed courses, such as the 6-month therapy period in the 2008 meta-analysis, and followed patients for months after the course ended. Those courses were set for chronic viral hepatitis under specialist care. The safety data summarized above also come from patients followed over defined treatment periods.

Online threads trade their own cycle lengths, from a few weeks to repeated courses through the year. None of those patterns has been tested in a controlled trial in healthy adults, so the record cannot say how long is useful or safe for that use. This is research context, not a protocol. How long, if at all, is a decision for a licensed clinician who reviews your history, your goals and how you respond.

References

  1. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology (PMC) (2020).
  2. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood (PubMed) (2004).
  3. Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. Clinical Infectious Diseases (PMC) (2020).
  4. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. FDA (2026).
  5. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.. Frontiers in immunology (2025).
  6. Thymosin alpha 1 treatment for patients with sepsis.. Expert opinion on biological therapy (2018).
  7. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.. International immunopharmacology (2023).
  8. Thymosin alpha-1.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2001).
  9. The effect of thymosin treatment of venous ulcers.. Annals of the New York Academy of Sciences (2010).
  10. Thymosin β4 Promotes Dermal Healing.. Vitamins and hormones (2016).
  11. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.. Journal of cellular and molecular medicine (2021).
  12. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.. Clinical ophthalmology (Auckland, N.Z.) (2015).
  13. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.. Cornea (2015).
  14. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.. Pharmaceutics (2026).
  15. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery (2025).
  16. The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin.. Annals of the New York Academy of Sciences (2009).
  17. Zinc: mechanisms of host defense.. The Journal of nutrition (2007).
  18. Precursors of thymic peptides as stress sensors.. Expert opinion on biological therapy (2020).

What Reddit says

r/covidlonghaulers235 points328 commentsFeb 2026

5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW!

A five-year long-Covid patient reports 500 mcg of thymosin alpha-1 subcutaneously with near-full symptom relief by day two or three, and the most substantive reply pushes back on the timeframe, attributing the early lift to macrophage activity and warning about tolerance. Three days of self-rated improvement after five years is exactly the pattern that does not hold up without follow-up, which the skeptic asks for; thymosin alpha-1 is an immune modulator, not a stimulant, and is not FDA approved in the US.

Posted on Reddit

Talk to a clinician about what's available.

Thymosin Alpha-1 is not currently on FDA's 503A Bulks List. PepScribe's programs and clinician-prescribed peptides give a clinician the room to review your goals and the options open to you.

Written by B.A. Utterback.

Educational information only. Not medical advice. Treatment decisions are made by a licensed physician.